glp 1 fgf21 agonist boehringer A novel GLP-1 and dual has therapeutic potential for diabetes and non-alcoholic steatohepatitis A peptide triple agonist of
Description
There are positive effects, such as healthy weight loss and help with managing type 2 diabetes, and downsides like potential side effects
This update summarizes the most clinically relevant developments
Hyperglycemia as a cardiovascular risk factor
It deserves a second look
States can decide whether to cover obesity drugs under Medicaid
